* Yield10 Bioscience Inc YTEN.OQ YTEN.O is expected
to show a
fall in quarterly revenue when it reports results on August
10.
* The Woburn Massachusetts-based company is expected to
report a
8.5% decrease in revenue to $159.25 thousand from $174 thousand
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Yield10 Bioscience
Inc is
for a loss of 69 cents per share. For the same quarter last
year, the company reported a loss of 64 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Yield10
Bioscience Inc is $9.5, above its last closing price of $2.52.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.65 -0.65 -0.68 Missed -4.2
Dec. 31 2022 -0.64 -0.63 -0.61 Beat 3.9
Sep. 30 2021 -0.65 -0.65 -0.49 Beat 24.6
Jun. 30 2021 -0.54 -0.54 -0.64 Missed -18.5
Mar. -0.54 -0.55 -0.60 Missed -8.1
31 2021
Dec. 31 2020 -0.70 -0.79 Missed -13.3
Sep. 30 2020 -0.95 -0.94 -0.87 Beat 7.9
Jun. 30 2020 -1.30 -1.30 -1.09 Beat 16.2
This summary was machine generated August 9 at 02:03 GMT. All
figures in US dollars unless otherwise stated